



Divi's Laboratories Limited

September 20, 2017

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza,
Bandra-Kurla Complex, Bandra (East)
MUMBAI – 400 051

To
The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI – 400 001

Stock Code: DIVISLAB

Stock Code: 532488

Dear Sir/ Madam,

Subject: Update on USFDA Inspection for Unit-2 at Visakhapatnam

We wish to inform that Divi's Laboratories Limited, Unit-2 has been inspected by US-FDA from September 11 to September 19, 2017.

This inspection was for full cGMP and verification of all Corrective Actions proposed against the previous Inspection observations. Divi's Laboratories Limited announces that all previous observations have been confirmed as completed and resolved.


On completion of this inspection, Divi's Laboratories Limited has received a Form 483 citing six observations which are procedural and the company will be responding to these within the stipulated time.

Disclaimer:

This is to inform that the statements in this document relating to the estimates or events may be "forward looking statements" within the meaning of the applicable securities regulations. Actual results, performance or events, financial or non-financial, could differ materially from those expressed or implied.

Thanking you,

Yours faithfully
For **Divi's Laboratories Limited**


P.V. Lakshmi Rajani
Company Secretary



"An ISO-9001, ISO-14001 and OHSAS-18001 Triple certified company"

Regd. Off. : Divi Towers, 1-72/23(P)/DIVIS/303, Cyber Hills, Gachibowli, Hyderabad - 500 032, Telangana, INDIA.

Tel : 91-40-2378 6300, Fax : 91-40-2378 6460, CIN : L24110TG1990PLC011854

E-mail : mail@divislaboratories.com, Website : www.divislaboratories.com